Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
HRYZ Biotech General Information
HRYZ Biotech is a Chinese biotech company specializing in engineered T-cell therapies, particularly TCR-T cell therapies targeting solid tumors. Its lead programs are in early clinical development, with some candidates reaching Phase 2 trials for advanced cancers such as urothelial carcinoma. The company has demonstrated preclinical efficacy of its proprietary engineered TCRs against targets like AFP and HPV18 E7, with ongoing efforts to improve potency and persistence of these cellular immunotherapies.[1][3][5][8][9]
Contact Information
Primary Industry
Biotech
Corporate Office
Shanghai, Shanghai
China
China
Drug Pipeline
MASCT-I
Phase 1Key Partnerships
Jiangsu Yuanzheng Cell Therapy Technology Co., Shenzhen Yuanzheng Cell Therapy Technology Co.[2]
HRYZ Biotech Funding
No funding data available
To view HRYZ Biotech's complete valuation and funding history, request access »